Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors), IL-5 inhibitors(Interleukin-5 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 06 Dec 2023 |